
The approval covers stroke patients at high risk of another event, while applications are still under review in the United States, Europe and Japan.
China has approved Bayer's Asundexian for stroke patients at high risk of another event, the company said. The drug had not previously received marketing approval.
Bayer said Asundexian is the first drug from the FXIa inhibitor class to reach the market worldwide. The company said preventive use reduced the risk of another stroke by 26%.
Applications are also under review in the United States, Europe and Japan. Morgan Stanley analysts have estimated the drug could reach peak annual sales of up to 4 billion euros.
As of 08:38 UTC, Bayer shares traded at 45.01 euros, up 2.34% since the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.